Amgen Inc. $AMGN Stock: Curated Wealth Partners LLC Decreases Holdings

Curated Wealth Partners LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 99.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,618 shares of the medical research company’s stock after selling 433,767 shares during the quarter. Curated Wealth Partners LLC’s holdings in Amgen were worth $682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Rational Advisors Inc. grew its holdings in Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after purchasing an additional 24 shares during the period. Beacon Financial Advisory LLC grew its stake in Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares during the period. Legacy Financial Advisors Inc. raised its position in shares of Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares during the period. Roman Butler Fullerton & Co. grew its holdings in shares of Amgen by 1.4% during the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock valued at $705,000 after buying an additional 27 shares during the last quarter. Finally, Round Rock Advisors LLC increased its position in shares of Amgen by 2.9% during the second quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock worth $363,000 after acquiring an additional 28 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.9%

Shares of AMGN opened at $434.03 on Friday. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The firm has a market capitalization of $234.65 billion, a price-to-earnings ratio of 26.98, a PEG ratio of 3.12 and a beta of 0.41. The firm’s 50-day moving average price is $415.11 and its 200-day moving average price is $374.35. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AMGN. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. TD Cowen boosted their price objective on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HSBC cut Amgen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. Finally, Guggenheim lowered their price objective on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $387.93.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
• Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
• Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
• Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.